Accessibility Menu

Alnylam Pharmaceuticals(FRA) DUL

Market Cap€27.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+4,061%
5 Year+24%
1 Year-46%
1 Month+17%
€207.30
+1.67%
+3.40Today
Alnylam Pharmaceuticals last closing stock price
MetricPriceDate
Last closeEUR 207.452026-08-31
Alnylam Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.29%EUR 202.802026-08-24
1 month+16.58%EUR 177.942026-07-31
3 month-15.77%EUR 246.302026-06-02
Year to date-38.71%EUR 338.502025-12-30
1 year-45.78%EUR 382.602025-08-29
3 year+10.58%EUR 187.602023-09-01
5 year+23.96%EUR 167.352021-09-01
Since inception+4,061.22%EUR 4.902004-05-31

Alnylam Pharmaceuticals Financials at a Glance

Market Cap

€27.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€4.12K

Net Income (TTM)

€692.56

EPS (TTM)

€5.08

P/E Ratio

40.16

Dividend

€0.00

Beta (Volatility)

0.08 (Low)

Price

€207.30

Volume

100

Open

€203.60

Previous Close

€207.30

Daily Range

€201.10 - €208.50

52-Week Range

€173.50 - €420.10

Estimated Earnings Date

N/A

DUL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Industry

Biotechnology

Sector

Health Care

Employees

2,500

CEO

Yvonne L. Greenstreet, MD, MBA

Website

www.alnylam.com

DUL Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

99.09%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

2.49%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€27.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

133.81M

Volume

100

Avg. Volume

50.015

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Alnylam Pharmaceuticals Performance Analysis

Alnylam Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 987,101,19138.2%
20232023-12-31EUR 1,691,116,09871.3%
20242024-12-31EUR 2,078,452,63222.9%
20252025-12-31EUR 3,290,811,23658.3%
Alnylam Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -8.8445.2%
20232023-12-31EUR -3.26-63.1%
20242024-12-31EUR -2.01-38.2%
20252025-12-31EUR 2.06N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€1.11K

+1.6%

Gross Profit

€853.61

+1.5%

Gross Margin

76.88%

+0.9%

Market Cap

€27.28BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€13.94

N/A

Employees

2,500

N/A

Net Income

€141.47

-2.4%

EBITDA

€211.01

-106.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€4.11K

+25.1%

Total Debt

€2.61K

+1.1%

Accounts Receivable

€798.34

+1.7%

Inventory

€84.94

+1.4%

Long Term Debt

€2.35K

+1.1%

Short Term Debt

€266.34

+2.2%

Return on Assets

15.83%

-2.1%

Return on Invested Capital

-19.71%

+0.7%

Free Cash Flow

€251.43

+1.9%

Operating Cash Flow

€281.38

+2.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About DUL

What is the current price of Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals is trading at €207.30 per share.

What is the 52-week range for Alnylam Pharmaceuticals?

Over the past 52 weeks, Alnylam Pharmaceuticals has traded between €173.50 and €420.10.

How much debt does Alnylam Pharmaceuticals have?

As of the most recent reporting period, Alnylam Pharmaceuticals reported total debt of €2.61B.

How much cash does Alnylam Pharmaceuticals have on hand?

Alnylam Pharmaceuticals reported €1.49B in cash and cash equivalents in its most recent financial results.

What is Alnylam Pharmaceuticals’s dividend yield?

Alnylam Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services